More likely in my mind that BP would buy Vyera out

More likely in my mind that BP would buy Vyera out of the HIV licensing deal. This would greatly simplify the issues with off-label usage, sales attribution, etc. Particularly if NASH were also involved with a given deal, due to the heavy overlap in the HIV/NASH patient populations.

It's just a thought though. I'd be perfectly happy to have Vyera sell a whole lot of leronlimab for us.